𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

✍ Scribed by Michalides, R; van Tinteren, H; Balkenende, A; Vermorken, J B; Benraadt, J; Huldij, J; van Diest, P

Book ID
109997125
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
127 KB
Volume
86
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Excellent outcomes with adjuvant toremif
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
✍ Jaime D. Lewis; Anees B. Chagpar; Elizabeth A. Shaughnessy; Jacob Nurko; Kelly M πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 184 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer wo

Evaluation of a displacement assay with
Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors
✍ Emanuel Levin; Andrea M. Actis; Silvana Caruso; Hugo Gass; Raquel Romero; NicolΓ‘ πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 95 KB πŸ‘ 2 views

A displacement assay with tamoxifen, based on the relative binding affinity of tamoxifen and estradiol for the estrogen receptor (ER), was proposed in 1990 as prognostic indicator for breast-cancer patients. Validation of its predictive results in relation to the outcome of 73 patients with ER Ψ‰ tum